: Disc Medicine, Inc. a pioneering clinical-stage biopharmaceutical firm, has recently reported encouraging outcomes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the APOLLO post-marketing confirmatory trial for bitopertin, targeting erythropoietic protoporphyria (EPP). Alongside the regulatory progress, a retrospective examination of the company’s fiscal performance reveals fluctuations in its working capital ratio, prompting a deeper analysis of its financial health and competitive stance within the biopharmaceutical sector. Erythropoietic protoporphyria (EPP) stands as a serious hematologic condition characterized by a deficiency of ferrochelatase, leading to the ...
Disc Medicine, Inc. a clinical-stage biopharmaceutical company, recently announced to present new clinical data from its ongoing Phase 1b trial of DISC-0974 at the 2024 American Society of Nephrology (ASN) Kidney Week. The trial focuses on patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia a population that has been significantly underserved in terms of adept treatment options. This article interprets the data to be shared during the event and assesses their potential impact on both patient outcomes and the future of Disc Medicine. Key Facts from the Announcement1. Event Details : The ASN Kidney Week will occur in San Diego, CA, from October 24-27, 2024. This timing aligns w...
Positive Clinical Data Across Disc Medicine s Portfolio Highlight Potential Advances in Hematologic Treatments BackgroundDisc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company, has made significant strides in developing novel treatments for serious hematologic diseases. Their recent presentation at the European Hematology Association (EHA) 2024 Congress showcased promising data from various clinical trials, aiming to improve patient outcomes for those suffering from erythropoietic protoporphyria (EPP), myelofibrosis (MF) anemia, and conditions requiring iron regulation. Bitopertin in Erythropoietic Protoporphyria Clinical Activity and AURORA DataDisc Medicine s lead candidate for EPP...
Disc Medicine, Inc. (NASDAQ:IRON) has recently presented updated positive results from the phase 2 BEACON study of bitopertin, an orally administered glycine transporter 1 (GlyT1) inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting. The study focused on patients with erythropoietic protoporphyria (EPP), a serious hematologic disease. The updated data presented by Disc Medicine validates the initial positive results highlighted in June. The findings demonstrate significant decreases in PPIX levels, along with robust and consistent improvements in sunlight tolerance across all study measures. Notably, this includes the achieving of an unprecedented pivotal endpoint. Additionally...
WATERTOWN, Mass., Nov. 14, 2023 - Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients suffering from severe hematologic diseases, has recently been granted an important patent by the United States Patent and Trademark Office (USPTO). The patent, No. 11,813,257, outlines novel methods of treating erythropoietic protoporphyrias (EPPs) using glycine transport inhibitors. Erythropoietic protoporphyrias (EPPs) are a group of rare and debilitating genetic disorders that affect the production of heme, a crucial component of red blood cells. Patients with EPPs experience an accumulation of protoporphyrin IX (PPIX), a photose...
Sources:
Disc Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Disc Medicine Inc’s corporate clients.
For your research, we’ve provided 9 tables on Disc Medicine Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
